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A common variant of the 
pregnancy-associated plasma 
protein-A (pAppA) gene encodes 
a protein with reduced proteolytic 
activity towards iGf-binding 
proteins
Jane Alrø Bøtkjær  1, pernille Rimmer noer2, claus oxvig2 & claus Yding Andersen1
pregnancy-associated plasma protein-A (pApp-A) is a key regulator of insulin-like growth factor (iGf) 
bioactivity, by releasing the iGfs from their corresponding iGf-binding proteins (iGfBps). the minor 
allele of the single nucleotide polymorphism (SNP), rs7020782 (serine < tyrosine), in PAPPA has 
previously been associated with recurrent pregnancy loss as well as with significant reduced levels 
of pApp-A protein in human ovarian follicles. the aim of the present study was to reveal a possible 
functional effect of the rs7020782 SNP in PAPPA by comparing recombinant pApp-A proteins from 
transfected human embryonic kidney 293 T cells. The proteolytic cleavage of IGFBP-4 was shown to be 
affected by the rs7020782 SNP in PAPPA, showing a significantly reduced cleavage rate for the serine 
variant compared to the tyrosine variant (p-value < 0.001). The serine variant also showed a trend 
towards reduced cleavage rates, that was not significant, towards IGFBP-2 and IGFBP-5 compared to 
the tyrosine variant. No differences were found when analysing cell surface binding, complex formation 
between PAPP-A and STC2 or proMBP, nor when analysing STC1 inhibition of PAPP-A-mediated 
IGFBP-4 cleavage. Regulation of IGF bioactivity in reproductive tissues is important and the rs7020782 
Snp in PAPPA may disturb this regulation by altering the specific activity of PAPP-A.
The insulin-like growth factor (IGF) signalling pathway is involved in several biological systems including the 
human reproductive system1–6. The two ligands, IGF-1 and -2, show high structural similarity to proinsulin and 
they interact and transduce their signal through the IGF-1 receptor and the insulin receptor with different affin-
ities7,8. Strict regulation of IGF bioactivity is crucial since abnormal levels of free IGFs in serum is sufficient 
to induce severe hypoglycaemic effects9. IGF bioactivity is antagonized by six different IGF binding proteins 
(IGFBPs), which bind the IGFs with equal or higher affinity than their receptors and thus prevent cellular signal-
ling. The IGFBPs also function to prolong the short half-life of IGFs in the circulation and direct them to their 
target receptor9–11. Different IGFBP proteinases exist, which release the IGFs from the IGFBPs by proteolysis12–14. 
The metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) is able to cleave IGFBP-2, IGFBP-4, 
and IGFBP-515,16. Proteolytic cleavage of IGFBP-4 by PAPP-A strictly depends on the binding of IGFs, whereas, 
PAPP-A cleavage of IGFBP-5 is slightly inhibited when bound to IGFs16. Originally, PAPP-A was detected in 
serum from pregnant women, where it circulates in complex with the proform of eosinophil major basic protein 
(proMBP), which functions as an inhibitor of the proteolytic activity of PAPP-A17,18. Currently, PAPP-A is used 
as a biomarker of foetal aneuploidies in pregnancies17. Two other inhibitors of PAPP-A, stanniocalcin-1 and 
-2 (STC1 and STC2), were recently discovered19–21. STC1 has been identified as a proteinase inhibitor towards 
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PAPP-A forming noncovalent high-affinity complexes19,20. In contrast, STC2 binds covalently to PAPP-A21. Thus, 
the STCs indirectly inhibit IGF signalling by counteracting PAPP-A activity, adding another level of regulation 
to the IGF system.
Previous studies have identified different essential protein modules in PAPP-A22–27. The C-terminal part 
of PAPP-A contains five complement control protein (CCP) modules. The CCP modules mediate adhesion of 
PAPP-A to the cell surface through glycosaminoglycans, thereby locating the release of the bioactive IGFs close 
to their corresponding receptors26,27.
A recent study found two inactivating mutations in PAPP-A2, a homolog of PAPP-A, in two independent 
families with growth failure and markedly lower free IGF-I levels5. In addition, carriers of a rare missense var-
iant in the STC2 gene (rs148833559) are approximately 2.1 cm taller compared to non-carriers28. Functional in 
vitro studies revealed that the ability of this variant to bind and inhibit PAPP-A-mediated IGFBP-4 cleavage was 
reduced, suggesting higher levels of bioactive IGFs that promote growth28. These earlier studies highlight the 
tremendous phenotypic effect small genetic variations may have. Previous studies have investigated single nucle-
otide polymorphisms (SNPs) in the PAPPA gene and one specific SNP in PAPPA; rs7020782, has been associated 
with increased risk of recurrent pregnancy loss, risk of gestational diabetes mellitus, risk of developing carotid 
plaques, and risk for ischemic cerebrovascular disease29–32. Additionally, a recent study revealed a significant effect 
of this SNP on the level of PAPP-A protein in human ovarian follicles and suggested a possible adverse effect on 
IGF bioactivity33. The rs7020782 SNP is located in exon 14 of the PAPPA gene in the CCP-1 module and causes a 
change in the amino acid sequence (i.e. tyrosine >serine). Furthermore, the glycosylation of these two variants 
may differ because the site of variation encodes a potential N-glycosylation motif22,23 and may hereby affect the 
properties of the protein, such as ability to bind substrates.
The frequency of the homozygous genotype of the minor allele (the CC genotype: serine variant) of the 
rs7020782 SNP is reported to be approximately 7–12% in Western and Asian populations34.
The present study aims to define a possible functional effect of the rs7020782 SNP in PAPPA by comparison of 
the recombinant protein variants. Throughout this paper we will address the two rs7020782 SNP variants as: the 
tyrosine variant and the serine variant.
Results
Surface binding of PAPP-A is not affected by the rs7020782 SNP. Cell surface binding of PAPP-A 
to human embryonic kidney 293 T (HEK293T) cells was assessed by flow cytometry and the geometric mean of 
fluorescence intensities was analysed (Fig. 1). No statistically significant (ns) difference was observed between 
HEK293T cells incubated with supernatant containing the serine variant (rPA_1144(Ser)) and HEK293T cells 
incubated with supernatant containing the tyrosine variant (rPA_1144(Tyr)) (Fig. 1). HEK293T cells incubated 
with supernatant without PAPP-A (MOCK) showed background fluorescence. Experiments were completed in 
triplicate and tested with two different primary antibodies against PAPP-A.
Complex formation between PAPP-A and its inhibitors: STC2 and proMBP. Complex formation 
between PAPP-A and STC2 or proMBP was studied by Western blot analysis. Supernatants from HEK293T cells 
transfected with the two rs7020782 PAPP-A variants incubated with supernatant containing STC2 (Fig. 2a,b) 
or proMBP (Fig. 2c,d) were examined. This analysis was performed to examine if the rs7020782 SNP in PAPPA 
influenced the covalent binding of PAPP-A to STC2 or proMBP.
Both STC2 and proMBP showed complex formation with the two different rs7020782 variants over time. 
These complexes were identified by a high molecular weight bands on the Western blot above the bands showing 
PAPP-A dimers (400 kDa). No difference was revealed with this Western blot analysis (Fig. 2).
Supernatants from HEK293T cells co-transfected with PAPP-A and STC2 (Fig. 2a,b: ‘co-trans’) or PAPP-A 
and proMBP (Fig. 2c,d: ‘co-trans’) were used as positive controls showing high molecular weight bands repre-
senting complete complex formation between PAPP-A and STC2 or proMBP. Supernatants from HEK293T cells 
transfected with PAPP-A alone (Serine variant: PA(Ser) or Tyrosine variant: PA(Tyr)) showed bands representing 
PAPP-A dimers solely at 400 kDa.
When incubating the two rs7020782 PAPP-A variants with supernatant from transfected HEK293T cells with 
empty vector (MOCK) no complex formation was observed (Supp. Fig. 2.1e). Experiments were completed in 
duplicate for both STC2 and proMBP.
Cleavage rate of IGFBP-2, -4, and -5 was lower for the serine variant compared to the tyrosine 
variant of the rs7020782 SNP in PAPPA. Proteolytic activity towards IGFBP-2, IGFBP-4, and IGFBP-5 
was assessed in order to examine whether the activity of PAPP-A was different between the two rs7020782 vari-
ants (Fig. 3).
Both rs7020782 variants of PAPP-A cleaved the three radiolabelled IGFBPs resulting in co-migrating cleav-
age products. Four independent proteinase assays revealed that the serine variant (rPA_1144(Ser)) presented 
a significantly lower cleavage rate of radiolabelled IGFBP-4 compared to the tyrosine variant (rPA_1144(Tyr)) 
(p-value < 0.001) (Fig. 3, upper panel). Furthermore, the results showed a trend towards reduced cleavage rates of 
radiolabelled IGFBP-2 and IGFBP-5 (Fig. 3, lower panel) for the serine variant compared to the tyrosine variant, 
which were derived from three independent proteinase assays.
STC1 binds and inhibits the proteolytic activity of both PAPP-A rs7020782 variants. Cleavage 
of radiolabelled IGFBP-4 by the two PAPP-A rs7020782 variants with increasing concentrations of STC1 was 
studied in order to evaluate a possible effect on STC1 inhibition (Fig. 4). The proteolytic activities of both PAPP-A 
rs7020782 variants were inhibited by STC1 showing decreasing cleavage rates with increasing concentrations of 
STC1. No significant difference was detected in this assay.
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Discussion
PAPP-A-induced IGF signalling has shown to be dependent and regulated by various factors, and these should be 
addressed when studying the functionality of PAPP-A. First, cell surface adherence of PAPP-A through the CCP 
modules facilitates IGF receptor activation by releasing bioactive IGFs close to their receptors on the target cell. 
Second, proMBP and STCs ensure strict regulation of PAPP-A by inactivating PAPP-A-mediated proteolysis of 
IGFBPs and thereby downregulate IGF signalling. Thus, when evaluating PAPP-A functionality it is important to 
address the ability of PAPP-A to bind cell surfaces and the ability of PAPP-A to form complexes with the inhibi-
tors in combination with studying its proteolytic activity.
This study provides a detailed analysis of potential functional effects of the rs7020782 SNP in the PAPPA 
gene using recombinant proteins from transfected HEK293T cells. The proteolytic activity of PAPP-A towards 
IGFBP-4 was significantly reduced for the serine variant of the rs7020782 SNP compared to the tyrosine variant 
(Fig. 3). Since PAPP-A acts as a crucial component in regulating IGF bioactivity, we suggest that the rs7020782 
SNP disturbs this regulation.
IGFBP-4 exhibits complex interaction with PAPP-A by interacting directly with substrate-binding exosite(s) 
in the LNR3 module of PAPP-A35. The rs7020782 SNP in PAPPA may disturb this proteinase/substrate interaction 
Figure 1. Detection of surface-bound PAPP-A by flow cytometry. Data are geometric mean (±SEM) of the 
log fluorescence intensity measured on a flow cytometer. Data are presented as mean values of the fluorescence 
intensity measured from HEK293T cells incubated with supernatants containing either the serine variant 
(rPA_1144(Ser): red bars) or the tyrosine variant (rPA_1144(Tyr): blue bars) of the rs7020782 PAPP-A SNP, or 
with supernatants with no PAPP-A (MOCK: black bars). Experiments were completed in triplicate and tested 
with two different primary antibodies against PAPP-A (Upper panel: PA6 antibody and lower panel: mAb 1/41 
antibody). No significant difference (ns) was observed between the two PAPP-A variants.
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and consequently result in the observed reduced proteolytic cleavage. In contrast, proteolysis of IGFBP-5 and 
IGFBP-2 by PAPP-A are not known to rely on specific interactions like IGFBP-4 and this may be the reason why 
the proteolytic cleavage of IGFBP-2 and IGFBP-5 only showed a trend towards reduced cleavage rates (not signif-
icant) for the serine variant of the rs7020782.
This study did not find any effect of the rs7020782 SNP on PAPP-A cell surface binding nor on the complex 
formation with the inhibitors proMBP and STC2. Additionally, the ability of STC1 to inhibit PAPP-A-mediated 
IGFBP-4 cleavage was not shown to be affected by the rs7020782 SNP.
As aforementioned, the rs7020782 SNP is located in exon 14 of PAPPA in the first CCP module22,23. 
Furthermore, only the serine variant allows for a potential N-glycosylation motif in the protein sequence at resi-
due Asn-1142, however, when the tyrosine variant is present the potential N-glycosylation motif is lost22,23. This 
could potentially exert a significant effect on the protein conformational structure and thereby modulate the 
proteolytic specificity of PAPP-A. We did not observe an effect of the rs7020782 SNP on the adhesion of PAPP-A 
to HEK293T cells, thus, the CCP modules do not seem to depend on this site for cell adhesion.
The serine variant of the rs7020782 SNP in PAPPA has previously been associated with various negative phys-
iological outcomes such as recurrent pregnancy loss29. Women carrying the rs7020782 SNP in PAPPA encoding 
the serine variant showed a tendency to have an increased risk of recurrent pregnancy loss, and a significantly 
increased risk of having at least one pregnancy loss after nine weeks of gestation29. Since the current study showed 
that the serine variant was associated with reduced IGFBP proteolysis, women carrying this variant might present 
with an altered IGF regulation and thereby a limited amount of free IGF to initiate signalling. Thus, the observed 
negative outcome on pregnancy is possibly affected by an altered IGF bioactivity through PAPP-A, most likely in 
combination with other genetic variations and aberrant levels of essential hormones.
In addition, adverse pregnancy outcomes have been associated with low levels of PAPP-A, for example an 
increased risk of intrauterine growth restriction, extremely premature delivery, preeclampsia, and stillbirth36. 
These studies highlight that the PAPP-A/IGF axis has an important function for pregnancy outcome.
A recent study displays a significant effect of the rs7020782 SNP in vivo33. Women carrying the homozygous 
CC genotype of the rs7020782 SNP (encoding the serine variant) displayed significantly lower concentrations of 
PAPP-A in follicle fluid (FF) of ovarian antral follicles compared to women carrying the major A allele (encoding 
the tyrosine variant). Additionally, reduced cleavage of radiolabelled IGFBP-4 was observed when incubated with 
FF from women with the serine variant, which was suggested to be explained by low PAPP-A levels. A tendency 
towards reduced estradiol levels and increased androgen levels in FF from women with the serine variant was also 
found, which was suggested to be influenced by an aberrant IGF regulation.
Figure 2. Complex formation of PAPP-A and STC2 or proMBP over time. Supernatants containing PAPP-A 
with either the serine (PA1144S) or the tyrosine (PA1144Y) variant of the rs7020782 SNP were incubated with 
STC2 (2a and 2b) or proMBP (2c and 2d) and formed covalent complexes over time (PAPP-A was incubated 
with STC2 or proMBP for 0, 1, 2, 4, 8, 16, and 24 hours). These protein complexes were visualized with Western 
blotting using a primary antibody against PAPP-A. A high molecular-weight band appears when complexes are 
formed (>400 kDa PAPP-A dimer). This figure displays PAPP-A incubated with STC2 from 0 to 2 h solely, since 
most PAPP-A has complexed with STC2 by this time-point and a potential difference would therefore be visible. 
Full-length blots and replications are presented in Supplementary Figs 2.1, 2.2. Supernatants from HEK293T 
cells co-transfected with both PAPP-A and STC2 or PAPP-A and proMBP were included in the Western blot as 
positive controls (co-trans) showing complexes exclusively. Supernatants from HEK293T cells transfected with 
PAPP-A alone (Serine variant: PA(Ser) or tyrosine variant: PA(Tyr)) was included as negative controls showing 
PAPP-A dimers solely. No difference was observed between the two PAPP-A variants in this Western blot 
analysis.
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Studies of cultured human cumulus cells isolated from women undergoing fertility treatment show impor-
tance of FSH together with IGF-1 receptor activity for maximal stimulation of estradiol production, further 
underlining the significance of IGF signalling for ovarian steroid production37.
Overall, the newly found effects of the rs7020782 SNP on PAPP-A proteolytic activity may impact on both 
human ovarian function and pregnancy outcome.
The observed significant effect of the rs7020782 SNP on PAPP-A-mediated IGFBP-4 cleavage showed an 
approximately 1.5-fold reduction. Whether this reduction will have biological influence cannot be concluded 
from the current study, but a recent study showed reduced cleavage of radiolabelled IGFBP-4 when incubated 
with ovarian FF from women carrying this SNP33, which supports this notion. However, the specific activity of 
PAPP-A was not assessed.
Previous studies have investigated the effect of assisted reproductive technology (ART) on first trimester 
screening parameters such as PAPP-A38,39. Significant lower PAPP-A serum levels have been found in women 
receiving IVF/ICSI treatment compared to women conceiving naturally. Furthermore, the low levels of PAPP-A 
were significantly correlated with high estradiol levels at ovulation induction39. This suggests a regulative role of 
the hormones produced in the ovary prior to conception on the PAPP-A/IGF axis. In addition, IVF and ICSI are 
known to result in a higher risk of low birth weight compared to normal pregnancies38,40. This is suggested to be 
affected by PAPP-A/IGF in a study showing that the combination of slow early foetal growth and low PAPP-A 
lead to an approximately six-fold increased risk of having a small for gestational age infant40. Thus, the lower level 
of PAPP-A in ART associated with high estradiol levels could potentially impact the growth and further develop-
ment of the foetus due to an abnormal IGF signalling.
Figure 3. Proteolytic activity of the two rs7020782 PAPP-A variants towards radiolabelled IGFBP-2, IGFBP-4, 
and IGFBP-5. Supernatants from HEK293T cells transfected with the two PAPP-A rs7020782 variants (serine: 
red, tyrosine: blue) were incubated with IGFBP-2 (lower panel), IGFBP-4 (upper panel), or IGFBP-5 (lower 
panel). Cleavage reactions were stopped at different time-points and subsequently, intact and cleaved IGFBPs 
were quantified (insert). IGFBP-4 cleavage in percent versus time (linear regression) as well as cleavage rates 
(mean ± SEM) for all three binding proteins are shown. Results showing IGFBP-4 proteolysis are derived 
from four independent proteinase assays and with supernatants from four independent transfections. Results 
showing IGFBP-2 and IGFBP-5 proteolysis are derived from three independents assays. A significantly lower 
IGFBP-4 cleavage rate was observed for the serine variant of the rs7020782 SNP compared to the tyrosine 
variant (p-value < 0.001). Reduced IGFBP-2 (p-value = 0.60) and IGFBP-5 (p-value = 0.78) cleavage rates that 
was not significant were observed for the serine variant compared to the tyrosine variant.
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Furthermore, women receiving IVF treatment and classified as poor responders for recombinant FSH have 
been shown to have significantly lower ovarian FF levels of IGF-1 together with lower serum and ovarian FF lev-
els of oestradiol and progesterone41. Furthermore, this study found a positive correlation between total oocytes 
retrieved and ovarian FF levels of IGF-1 and suggests that the observed decreased level of IGF-1 in poor respond-
ers impairs the ovarian steroid production.
The minor allele of the investigated rs7020782 SNP (serine variant) appears to have potentially adverse effects 
on reproduction but persists at non-negligible frequencies. A potential explanation is that carrying a single copy 
of the minor allele may either have no phenotypic effect or, in some cases, even lead to potential beneficial effects, 
in for instance, breast and ovarian cancer where PAPP-A has shown to have tumour-promoting properties42. 
Alternatively, the minor allele may only show adverse effects in a certain genetic background, as, for instance, 
in Sub-Saharan Africa where the serine allele of the rs7020782 SNP instead of being the minor allele has been 
reported to be the major allele, which is exactly opposite to European and Asian populations34.
Besides recurrent pregnancy loss the rs7020782 SNP in PAPPA also associates with the risk of gestational dia-
betes mellitus, risk of developing carotid plaques, and risk for ischemic cerebrovascular disease30–32. An altered 
IGF bioactivity may be present in these cases, because of the reduced proteolysis of IGFBPs by PAPP-A, however, 
none of these studies included examinations of PAPP-A activity.
This study shows, for the first time, a direct link between the rs7020782 SNP in PAPPA and reduced proteolytic 
function, specifically towards IGFBP-4, which may be explained by reduced proteinase/substrate interaction. This 
may partly explain some of the mechanisms behind the different diseases associated with the SNP and highlights 
the importance of the IGF pathways in different biological aspects.
We suggest that the rs7020782 SNP in PAPPA could be used as a biomarker for identifying women with high risk of 
adverse pregnancy outcomes such as recurrent pregnancy loss and perhaps this could even allow for risk-specific treat-
ment and improve the outcomes for these patients, however, further studies are needed to apply this in clinical settings.
Materials and Methods
Mutagenesis. Plasmids encoding human PAPP-A with the tyrosine variant of the rs7020782 SNP were con-
structed with the QuickChange II site-directed mutagenesis kit (Stratagene) using the primers:
5′-ctggctgtggagaatgcttatctcaattgctccag-3′ (forward primer)
5′-ctggagcaattgagataagcattctccacagccag-3′ (reverse primer)
(the rs7020782 change is underlined in the primer sequences).
Human PAPP-A plasmid (pcDNA3.1-PAPP-A) was used as a template described previously18,27. The PAPP-A 
constructs were verified with sequencing. The rs7020782 PAPP-A variant that encodes the serine variant was 
present in the pcDNA3.1-PAPP-A plasmid.
cell culture and transfection. HEK293T cells were maintained in high glucose Dulbecco’s modified Eagle’s 
medium supplemented with 10% foetal bovine serum, 2 mM glutamine, nonessential amino acids, and gentamicin 
(Invitrogen). Cells were plated in 6-cm tissue culture dishes and transfected with plasmid constructs containing cDNA 
encoding: human PAPP-A with the serine variant of the rs7020782 SNP, human PAPP-A with the tyrosine variant 
of the rs7020782 SNP, human proMBP (Human placental oligo-dT-primed cDNA encoding proMBP was used as a 
template43) and human STC2 (STC2 cDNA in the pcDNA3.1/Myc-His(−) was used as a template21). HEK293T cells 
transfected with empty vector were included as controls (MOCK). Transfection of cells was performed by calcium 
Figure 4. STC1 inhibition of PAPP-A-mediated IGFBP-4 cleavage. Relative initial velocities (v/v0) of PAPP-
A-mediated IGFBP-4 cleavage (mean ± SEM) are plotted against logarithmic values of STC1 (M). Velocities 
are calculated from 3 time-points (15 min, 30 min, and 45 min) for each rs7020782 variant in the presence of 
increasing concentrations of STC1 (0.001 nM, 0.0312 nM, 0.0625 nM, 0.125 nM, 0.25 nM, 0.5 nM, and 1.0 nM) 
relative to the velocity without STC1. Data are fitted to a non-linear regression curve using ‘log(inhibitor) vs. 
response – variable slope’ in GraphPad Prism 5.0. The serine variant of the rs7020782 SNP is displayed in red 
and the tyrosine variant in blue. No significant difference was observed.
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phosphate co-precipitation using 10 µg of plasmid DNA as previous described21. Media were harvested 24 hours and 
48 hours post-transfection, cleared by centrifugation, and stored at -20 °C until further analysis.
enzyme-linked immunosorbent assay (eLiSA). The concentration of recombinant PAPP-A in the 
supernatants from the transfected HEK293T cells was determined by ELISA (picoPAPP-A, AL-101-i, Ansh Labs, 
Texas, USA) according to the manufacturer’s instructions (PBS + 1% BSA was used for dilution). The ELISA 
measures were used to achieve equal concentration of the two PAPP-A rs7020782 variants in the different func-
tional assays.
flow cytometry. HEK293T cells were used for analysing cell surface adhesion of the PAPP-A rs7020782 
variants27. Non-transfected cultured HEK293T cells were incubated on ice with supernatant containing the ser-
ine variant of the rs7020782 SNP, the tyrosine variant of the rs7020782 SNP, or supernatant from HEK293T cells 
transfected with empty vector (MOCK) for 1 hour. A total of 800,000 cells/well were used. After incubation the 
cells were washed four times with 1% BSA in PBS and subsequently incubated with primary antibody against 
PAPP-A (two different antibodies were used: mAb 1/4144 and PA620, both at a concentration of 10 µg/ml) for 
30 min on ice. The cells were washed three times with 1% BSA in PBS and incubated with Alexa Fluor TM 488 
goat anti mouse (Invitrogen A11029, 1:300) for 43 min on ice. After three washes, the cells were suspended and 
fixated in PBS with 2% paraformaldehyde and analysed on a Gallios Flow Cytometer. The 488 nm laser for excita-
tion and FL1 (525/50 bandpass filter) detector for emission were used on the flow cytometer. The time-of-flight 
versus peak height analysis of forward scatter (FS) was used to exclude cell doublets, and a total of approximately 
10,000–14,000 cells were gated for analysis in the software program FlowJo (version 10.5.2).
Western blotting. In order to investigate the ability of the two rs7020782 PAPP-A variants to form com-
plexes with STC2 and proMBP Western blotting was performed. Supernatants harvested from the HEK293T cells 
transfected with either of the two rs7020782 PAPP-A constructs, STC2, proMBP, or with empty vector (MOCK) 
as a negative control was used for Western blotting as previously described20. To remove possible traces of endog-
enous STC2 present in the media containing recombinant PAPP-A, immunoprecipitation of the culture media 
was carried out by incubating (16 h at 4 °C) 1 ml culture media with 30 ul protein G-Sepharose 4 Fast Flow beads 
(GE Healthcare, Denmark) coupled to 2 mg/ml of murine monoclonal antibodies against STC2 (STC22120,) as 
described previously20. Supernatants with either of the PAPP-A variants were incubated with STC2 or proMBP 
for 0, 1, 2, 4, 8, 16, and 24 hours (h) or with empty vector (MOCK) for 0, 8, and 24 h at 37 °C. STC2, proMBP 
and PAPP-A were blotted onto PVDF membranes (Millipore) following separation by 3–8% SDS-PAGE. For 
PAPP-A/STC2 and PAPP-A/proMBP complex detection, the membranes were incubated with rabbit polyclonal 
anti-PAPP-A at 0.63 μg/ml in TST supplemented with 2% skim milk for 16 h at 20 °C45. Membranes were washed 
with TST and subsequently incubated with polyclonal swine anti-rabbit IgG-HRP (DAKO, P0217) in TST sup-
plemented with 2% skim milk for 1 h at 20 °C. Blots were developed using enhanced chemiluminescence (ECL 
Prime, GE Healthcare). Images were captured using an ImageQuant LAS 4000 instrument (GE Healthcare) (ECL; 
Amersham Pharmacia Biotech).
The PageRuler™ Plus Prestained Protein Ladder, 10 to 250 kDa was used as marker (Catalog number: 26619, 
Thermo Scientific™).
proteinase assay. To measure the proteolytic activity of PAPP-A in the supernatants harvested from the 
HEK293T cells transfected with either of the two rs7020782 variants, a proteinase assay based on autoradiography 
was performed as previously described in detail16. Proteinase assays were performed by measuring the proteolytic 
cleavage of radiolabelled IGFBP-2, IGFBP-4, and IGFBP-5. Different PAPP-A concentrations were used in the 
three assays, which were optimized for the variants to achieve cleavage percentages below 30%, where a linear 
relationship between time and cleavage can be assumed, and the cleavage rates are hereby determined by the 
slopes16. For the IGFBP-2 cleavage assay the PAPP-A concentration was adjusted to 10 nM, for the IGFBP-4 assay 
PAPP-A concentration was adjusted to 150 pM and for the IGFBP-5 assay the PAPP-A concentration was adjusted 
80 pM. Intact and cleaved IGFBPs were quantified with the ImageQuant TL 8.1 software (GE Healthcare).
Addition of increasing concentrations of STC1 was performed in a separate IGFBP-4 cleavage assay to exam-
ine if the inhibition of PAPP-A was different between the two rs7020782 PAPP-A variants. The STC1 concentra-
tions used in the assay were: 0.001 nM, 0.0312 nM, 0.0625 nM, 0.125 nM, 0.25 nM, 0.5 nM, and 1.0 nM19.
Statistical analysis. An unpaired t-test was used to test significant difference in cleavage rate of IGFBP-2, 
IGFBP-4, and IGFBP-5 between the two rs7020782 PAPP-A variants. The same model was used to test significant 
differences in STC1 inhibition of PAPP-A activity and the cell surface binding ability. The p-value was set to 0.05 
to assess statistical significance.
Data Availability
Data generated during this study are made available in the supplementary files. Additional data generated and 
analysed during the current study are available from the corresponding author on reasonable request.
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